Latest news and press releases about Dr. Reddy's Laboratories Limited (RDY): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products.
Price
| Price | $12.32 |
| Market Cap | $10.3B |
| Exchange | NYSE |
| Country | IN |
Valuation Ratios
| P/E Ratio | 30.37 |
| Price / Book | 2.62 |
| EV / EBITDA | 13.66 |
| Dividend Yield | 0.66% |
Profitability
| Return on Equity | 12.20% |
| Return on Invested Capital | 8.10% |
| Return on Assets | 7.94% |
| Gross Margin | 50.18% |
| Operating Margin | 10.64% |
| Net Margin | 10.00% |
Related companies: BMRN · EHC · ELAN · ENSG · EXEL · NBIX · RVMD
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of RDY: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks